Global Rett Syndrome Pipeline Review, H2 2020: 32 Companies, Drug Profiles, Dormant Projects, Discontinued Products, Development Milestones – ResearchAndMarkets.com

Global Rett Syndrome Pipeline Review, H2 2020: 32 Companies, Drug Profiles, Dormant Projects, Discontinued Products, Development Milestones – ResearchAndMarkets.com




Global Rett Syndrome Pipeline Review, H2 2020: 32 Companies, Drug Profiles, Dormant Projects, Discontinued Products, Development Milestones – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Rett Syndrome – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Rett Syndrome – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 11 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

  • Introduction
  • Rett Syndrome – Overview
  • Rett Syndrome – Therapeutics Development
  • Rett Syndrome – Therapeutics Assessment
  • Rett Syndrome – Companies Involved in Therapeutics Development
  • Rett Syndrome – Drug Profiles
  • Rett Syndrome – Dormant Projects
  • Rett Syndrome – Discontinued Products
  • Rett Syndrome – Product Development Milestones
  • Appendix

Companies Mentioned

  • Amicus Therapeutics Inc
  • AMO Pharma Ltd
  • Amorsa Therapeutics Inc
  • Anavex Life Sciences Corp
  • ArmaGen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • BioXcel Corp
  • CuroNZ Ltd
  • DepYmed Inc
  • Echo Pharmaceuticals BV
  • Eloxx Pharmaceuticals Inc
  • Epeius Pharma Co
  • Epigen Biosciences Inc
  • EuMentis Therapeutics Inc
  • GW Pharmaceuticals Plc
  • Lucy Therapeutics Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neuren Pharmaceuticals Ltd
  • Neurolixis Inc
  • Neurotrope Bioscience Inc
  • Novartis Gene Therapies
  • PharmatrophiX Inc
  • Prilenia Therapeutics Development Ltd
  • PTC Therapeutics Inc
  • Recursion Pharmaceuticals Inc
  • Relmada Therapeutics Inc
  • Starwise Therapeutics LLC
  • StrideBio Inc
  • Taysha Gene Therapies
  • Thiogenesis Therapeutics SARL
  • Ultragenyx Pharmaceutical Inc
  • Vico Therapeutics BV

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sbjbda

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900